2021
Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer.
Laws A, Garrido-Castro A, Poorvu P, Winer E, Mittendorf E, King T. Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer. Oncology 2021, 35: 77-84. PMID: 33577165, DOI: 10.46883/onc.2021.3502.0077.Peer-Reviewed Original ResearchConceptsRecurrence scorePositive nodesClinical trialsBreast cancerHER2-negative breast cancerNode-positive breast cancerLarge population-based registryNode-positive populationAdjuvant chemotherapy useChemotherapy-treated patientsClinical practice guidelinesCurrent practice patternsPopulation-based registryMultiple clinical trialsPotential predictive valueADAPT trialAdjuvant chemotherapyChemotherapy useEndocrine therapyPostmenopausal patientsChemotherapy benefitExcellent outcomesPractice patternsPractice guidelinesRetrospective analysis
2010
Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer
Freedman RA, Winer EP. Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer. The Breast 2010, 19: 69-75. PMID: 20034796, DOI: 10.1016/j.breast.2009.11.009.Peer-Reviewed Original ResearchConceptsEndocrine-sensitive breast cancerAdjuvant endocrine therapyBreast cancerEndocrine therapyPostmenopausal womenEndocrine-sensitive tumorsMultiple clinical trialsAdjuvant therapyClinical trialsTreatment benefitCurrent recommendationsTherapyAvailable evidenceTranslational questionsCancerWomenFuture studiesTumorsTrials